Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S, Hassel JC, Hauschild A, Herbst R, Jiang R, Kaatz M, Kahler K, Krepler C, Kreuter A, Leiter-Stoppke U, Loquai C, Meier F, Pfohler C, Rudolph A, Schadendorf D, Schiavone M, Schley G, Terheyden P, Ugurel S, Ulrich J, Utikal JS, Weishaupt C, Welzel J, Weichenthal M (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 18-18
Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
APA:
Mohr, P., Scherrer, E., Alar, V., Assaf, C., Beissert, S., Berking, C.,... Weichenthal, M. (2022). Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 18-18). HOBOKEN: WILEY.
MLA:
Mohr, P., et al. "Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2022. 18-18.
BibTeX: Download